TABLE 2.
Immunostaining of MT-3 in all diagnostic categories.
| Type | |||||
|---|---|---|---|---|---|
| Invasive Carcinomas | N | % Positive | Quick Score Average | SEM +/− | |
| IDC | Invasive Ductal Carcinoma | 131 | 87.8% | 11.626 | 0.548 |
| ILC | Lobular Carcinoma | 25 | 76.0% | 10.273 | 1.143 |
| MixD/L | Mixed Ductal and Lobular Carcinoma | 14 | 92.9% | 12.500 | 1.493 |
| MixD/O | Mixed Ductal/Other type | 8 | 100.0% | 13.250 | 2.144 |
| Other | Other types (SPC, Papillary, Comedo, Apocrine) | 5 | 100.0% | 14.000 | 1.673 |
| GoodST | Other types (good prognosis – medullary, mucinous, tubular) | 13 | 69.2% | 5.143 | 1.410 |
| BadST | Other types “Inflammatory” (poor prognosis) | 2 |
100.0% | 14.000 | 4.000 |
| 198 | |||||
| Carcinoma in Situ | N | % Positive | Quick Score Average | SEM +/− | |
| DCIS | Ductal Carcinoma in Situ | 84 | 92.9% | 12.404 | 0.602 |
| LCIS | Lobular Carcinoma in Situ | 13 | 84.6% | 12.938 | 1.510 |
| D/L CIS | Mixed DCIS/LCIS | 5 |
100.0% | 12.000 | 3.146 |
| 102 | |||||
| Invasive Ductal Grading | N | % Positive | Quick Score Average | SEM +/− | |
| ICD-3 | 78 | 91.0% | 12.052 | 0.805 | |
| IDC-2 | 58 | 89.7% | 10.526 | 1.655 | |
| IDC-1 | 19 | 78.9% | 10.273 | 1.143 | |